Health Care & Life Sciences » Biotechnology | Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC

Adaptimmune Therapeutics PLC ADR
Stock Exchange Frankfurt Stock Exchange
EPS
EUR0.89
Market Cap
EUR345.6 M
Shares Outstanding
104.45 M
Public Float
-
Adaptimmune Therapeutics PLC ADR
Stock Exchange NASDAQ Stock Market
EPS
$1.03
Market Cap
$387.49 M
Shares Outstanding
104.71 M
Public Float
86.21 M

Profile

Address
60 Jubilee Avenue
Abingdon Oxfordshire OX14 4RX
United Kingdom
Employees -
Website http://adaptimmune.com
Updated 07/08/2019
Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K.

Financials

View All
Created with Highcharts 5.0.14Adaptimmune Therapeutics PLC ADRNet Income. Fiscal year is January-December. All values USD Thousands.8 7328 73212 20912 20922 45022 45071 08471 08470 89070 89095 35295 352201320142015201620172018025k50k75k100k125k
Created with Highcharts 5.0.14Adaptimmune Therapeutics PLC ADRSales/Revenue. Fiscal year is January-December. All values USD Thousands.0058158116 77516 77514 10014 10038 23838 23859 40459 404201320142015201620172018010k20k30k40k50k60k70k

James Julian Noble
Chief Executive Officer & Executive Director
David M. Mott
Chairman